Madras, the director of McLean’s Laboratory of Addiction Neurobiology, accepted the award on June 16, 2019, at CPDD’s 81st Annual Scientific Meeting in San Antonio, Texas.
According to CPDD, the annual award recognizes “individuals who have developed innovative approaches in basic science, clinical research, or treatment and prevention science that reflect groundbreaking strides with potential for significant impact in the field of drug dependence.” Indivior, a maker of opioid addiction treatment drugs, sponsors the Innovator Award.
On receiving the honor, Madras said, “I was honored to receive this recognition from my colleagues and peers. Above all, the award provided an opportunity to express my deep gratitude to the wonderful collaborators and colleagues that contributed significantly to various components of the research, and to McLean Hospital for providing me with a magnificent home base.”
The CPDD recognized Madras for her work as the discoverer of a class of compounds called phenyltropanes, which can be used for brain PET and SPECT imaging of dopamine neurons.